Seeking to Join Editas, Intellia, CRISPR Therapeutics Makes Long Awaited IPO Push
By Ben Fidler,
Xconomy
| 09. 12. 2016
Investors hoping to buy into the vast, yet still unproven drugmaking potential of the gene editing system CRISPR-Cas9 will soon have three different companies to choose from. CRISPR Therapeutics filed for an IPO on Friday, meaning it could soon join Boston-area rivals Editas Medicine and Intellia Therapeutics in the expanding club of publicly traded CRISPR-Cas9 drug developers.
Basel, Switzerland- and Cambridge, MA-based CRISPR has been slowly amassing rounds of venture funding, adding partners, and filling out an executive team over the past few years. Editas (NASDAQ: EDIT) and Intellia (NASDAQ: NTLA) have each gone public in 2016, and CRISPR has long been expected to join them. Should CRISPR complete the IPO, it’ll trade on the Nasdaq under the ticker symbol “CRSP.”
Over the past several years, CRISPR-Cas9 has captured the imaginations of scientists and drugmakers alike. It’s a tool currently used in research labs across the globe that one day might help perform genetic surgery to correct devastating diseases. There’s a long way to go first, of course. CRISPR-based therapies have only just begun their first clinical tests...
Related Articles
By Anna Collinson and Jo Adnitt, BBC | 08.18.2026
At least 30 children, most of them British, are feared to have been conceived by IVF treatment in northern Cyprus using the wrong sperm or egg donors.
In each case, the parents suspect they did not get the donors they...
By Hamed Aleaziz, The New York Times | 08.13.2026
Immigrants at Ellis Island undergoing a medical inspection | Photo by The New York Public Library on Unsplash
In 1924, Congress sent a message to the world: We are no longer ready to take “your tired, your poor, your huddled...
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
